Thus, characterization of the EBV status of HRS cells in newly diagnosed cHL patients might be essential for future immunotherapeutic approaches that may include antibodies targeting CD16 and therefore rely on functional NK cell-mediated ADCC. The gene discussed is FCGR3A; the disease is classic Hodgkin lymphoma.